Intervenciones educacionales para incrementar la farmacovigilancia en una unidad de salud de familia

Educational interventions to increase pharmacovigilance in a family health unit

Mr Editor:

Adverse drug reactions (ADRs) are a relevant public health problem and a significant cause of mortality and hospitalization in developed countries, representing about 6.5 % of total hospitalizations [1]. It is estimated that most adverse reactions are detected only in the post-marketing stage, denoting the relevance of a constant drug surveillance system through pharmacovigilance activities after drugs are placed on the market. The Portuguese Pharmacovigilance System is essentially based on the unsolicited notification of suspected ADRs by health professionals to the National Authority, generating warning signs. Despite the legal imperative [2], the primary limitation to the effectiveness of this notification system is underreporting, with several studies indicating that less than 10 % of ADRs are notified to regulatory authorities [3] (Figure 1). Thus, according to data from Infarmed [4], the number of ADR notifications received by the National Pharmacovigilance System has been increasing considerably.

Rita Ribeiro Barbosa 2,a, Ana Filipa Fontes 2,a, Joana Nuno 1,2,a, Susana Fernandes 2,a, Dinis Brito 1,2,a

1 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
2 Unidade de Saúde Familiar 7 fontes, ACeS Cavadão, ARSNorte, Braga, Portugal.
a Médico de Familia.

Figure 1: Pharmacovigilance has emerged as an essential tool for quaternary prevention and has become a fundamental activity for the rational and safe use of drugs and Public Health protection. Underreporting ADRs is a very well-known phenomenon. The negative factors influencing ADR reporting are based on the “seven deadly sins”, as proposed by Inman 7.

- Inman’s 7 deadly sins
  - Complacency
  - Fear
  - Guilt
  - Ambition
  - Lack of awareness
  - Insecurity
  - Indifference

- Rational and safe drugs’ use
- Detection, assessment, and Prevention of ADRs
- Counteract underreporting
- Pharmacovigilance
- ADRs reporting systems
- Quaternary prevention
- Patient empowerment
- Medication Reconciliation
- Public health protection
Suspected and undescribed ADRs are the most relevant data for pharmacovigilance systems \[4\]. However, it is still relevant to monitor already known and documented ADRs for aspects such as possible changes in frequency, time to onset, duration, extension, and association with a specific, pharmacotherapeutic, or pathophysiological profile of the patient.

This work mainly aimed to develop pharmacovigilance strategies in the Family Heath Unit (FHU) related to the detection of adverse drug reactions. It also intended to increase basic pharmacovigilance \[5\], knowledge and competencies of different professionals and disseminate the online “Portal RAM” tool created by the National Authority for Medicines and Health Products I.P. in 2012 and redesigned in 2017, as the preferred tool for reporting ADRs. We assumed the goal of tripling the number of unsolicited ADR reports for 2018 (n=4) by direct notification. The development of these competencies was promoted through a training session in April 2019, focused on the following objectives in Infarmed’s 2018 Case Report \[5-6\], specifically targeting data related to health professionals’ direct life notifications and related to Guimarães Pharmacovigilance Unit and the number of notifications made by the FHU in 2018. Online tool Portal RAM was presented with an interactive explanation of its operation. Brief interventions of varying length were also carried out throughout the year to clarify concerns and consolidate strategies. Twenty-three notifications were obtained, representing an increase of more than 500 % (Table 1)

The month with the highest number of reports was expectedly May, the closest to the training action. Although a dilution effect was observed over time, all months recorded notifications. Noteworthy is that nurses did not contribute to this result as was observed over time, all months recorded notifications. This experience encourages the need to maintain continuous intervention programs, with the involvement of nurses and other agents such as pharmacists to improve the ADR reporting rate \[6\]. The development of these strategies in primary health care and the consequently improved knowledge of the different drugs’ safety profile ultimately ensures more robust protection of Public Health since its target population is not limited to users of functional units \[10\].

| Month       | Direct notifications |
|-------------|----------------------|
|             | Doctor | Nurse | Total |
| May         | 6      | 0     | 6     |
| June        | 3      | 0     | 3     |
| July        | 5      | 0     | 5     |
| August      | 5      | 0     | 5     |
| September   | 2      | 0     | 2     |
| October     | 2      | 0     | 2     |

| Table 1. |

This experience encourages the need to maintain continuous intervention programs, with the involvement of nurses and other agents such as pharmacists to improve the ADR reporting rate \[6\]. The development of these strategies in primary health care and the consequently improved knowledge of the different drugs’ safety profile ultimately ensures more robust protection of Public Health since its target population is not limited to users of functional units \[10\].

Contribuciones de autoría: Todos los autores contribuyeron en todas las secciones de esta comunicación.

Potenciales conflictos de interés: Los autores declaran no tener posibles conflictos de interés.

Fuentes de financiamiento: Autofinanciado.

ORCID

Dinis Brito, https://orcid.org/0000-0002-7547-0053
Rita Ribeiro Barbosa, https://orcid.org/0000-0002-5728-9840
Ana Filipa Fontes, https://orcid.org/0000-0002-5474-4748
Joana Nuno, https://orcid.org/0000-0003-3536-4296
Susana Fernandes, https://orcid.org/0000-0003-3785-482X

REFERENCES

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9. doi: 10.1136/bmj.329.7456.15. PMID: 15231615; PMCID: PMC443443.
2. Ministério da Saúde. (2006, Aug.30). Decreto-Lei n.º 176/2006, D. R. I série. 167 [online]. https://dre.pt/application/file/a/540322.
3. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385-96. doi: 10.2165/00002018-200629050-00003. PMID: 16689555.
4. Infarmed. Relatório Anual Casuística 2018 do Infarmed [Internet]. Portugal; 2018. [cited 21/11/2021 ]. Available: https://www.infarmed.pt/documents/15786/2099374/Relat%C3%83rio+Anual+Casu%C3%83stica+2018/b3b74cab-d176-4c6a-adb9-9371589d75e9.
5. May F. Teaching and Learning Pharmacovigilance. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed: John Wiley & Sons, Ltd; 2007. p. 621-32.
6. Bigi C, Bocci G. The key role of clinical and community health nurses in pharmacovigilance. Eur J Clin Pharmacol. 2017 Nov;73(11):1379-1387. doi: 10.1007/s00228-017-2309-0. Epub 2017 Aug 2. PMID: 28770283.
7. Ribeiro-Vaz I, Herdeiro MT, Polónia J, Figueiras A. Strategies to increase the sensitivity of pharmacovigilance in Portugal. Rev Saude Publica. 2011 Feb;45(1):129-35. doi: 10.1590/s0034-89102010005000050. Epub 2010 Nov 12. PMID: 21085884.

8. Shchory MP, Goldstein LH, Arcavi L, Shihmaner R, Berkovitch M, Levy A. The effect of an intervention program on the knowledge and attitudes among medical staff regarding adverse drug reaction reporting. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1246-1253. doi:10.1002/pds.5013. Epub 2020 Apr 21. PMID: 32316074.

9. Passier A, ten Napel M, van Grootheest K, van Puijenbroek E. Reporting of adverse drug reactions by general practitioners: a questionnaire-based study in the Netherlands. Drug Saf. 2009;32(10):851-8. doi: 10.2165/11314490-000000000-00000. PMID: 19722728.

10. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19-31. doi: 10.2165/00002018-200932010-00002. PMID: 19132802.